IDeA Reauthorization Act of 2025

Bill Number

S. 2005

Origin Chamber

Senate

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-06-10: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Last Updated

2025-06-30T13:05:03Z

AI-Generated Summary

Purpose

The IDeA Reauthorization Act of 2025 aims to enhance the Institutional Development Award (IDeA) program of the National Institutes of Health (NIH) by formalizing its name, clarifying eligibility for participating states, and introducing new reporting requirements to promote transparency, integration, and measurable progress in biomedical and behavioral research in underserved areas.

Key Provisions

• Program Naming and Scope: Officially designates the program as the "Institutional Development Award program" or "IDeA program." It supports entities conducting biomedical or behavioral research in states with limited NIH funding.
• Eligibility Criteria for States: Defines "IDeA States" as those at or below the median level of all states in total NIH grant funding (excluding IDeA funds), based on a rolling multi-year average calculated by the NIH Director.
• Annual Reporting Requirements: NIH must provide Congress, as part of its federal budget submission or via a publicly accessible online data source, an annual report including:
• The program's strategy and objectives.
• Details on awards from the previous fiscal year, such as efforts to integrate IDeA States into broader NIH activities, the percentage of grant reviewers from IDeA States, and updates on collaborative awards between IDeA and non-IDeA states.
• Progress over the last five fiscal years in improving academic research quality and developing human resources in biomedical sciences.

Significant Changes to Existing Law

This bill amends Section 461(b)(1) of the Public Health Service Act (42 U.S.C. 285k(b)(1)):

• Adds an explicit name for the program, which was previously informal.
• Revises the definition of eligible entities to focus on states below the national median in NIH funding, using a multi-year average for stability (previously, eligibility may have been less precisely defined).
• Introduces mandatory annual reporting on program performance and integration, which was not required before, to ensure accountability and public access to data.

Potential Impacts

• On Government Agencies: NIH will face increased administrative burdens for calculating state eligibility and producing detailed annual reports, potentially improving program oversight and resource allocation to underfunded research hubs.
• On Citizens and Researchers: Residents and institutions in lower-funded states (IDeA States) may gain better access to research funding, fostering local scientific talent and innovation. This could reduce geographic disparities in health research opportunities across the U.S.
• On International Relations: Minimal direct impact, as the bill focuses on domestic U.S. research funding; however, stronger U.S. biomedical capabilities could indirectly enhance global health collaborations.

Main Stakeholders Affected

• NIH and Federal Agencies: Directly responsible for implementing changes, eligibility determinations, and reporting.
• Research Institutions in IDeA States: Universities, hospitals, and labs in states with below-median NIH funding (e.g., potentially rural or less populous states) stand to benefit from targeted awards and integration into national initiatives.
• Researchers and Students: Biomedical and behavioral scientists, particularly in underserved areas, may see improved funding access, reviewer diversity, and career development opportunities.
• Congress and the Public: Gain transparency through required reports, enabling better evaluation of taxpayer-funded research programs.
• Non-IDeA States: Could participate in partnerships but may experience shifts in overall NIH funding distribution.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens accountability under the Public Health Service Act by mandating data-driven reporting, potentially setting a precedent for similar transparency in other NIH programs without altering funding authorizations.
• Constitutional: Aligns with Congress's spending power (Article I, Section 8) to promote general welfare through equitable research distribution; no apparent conflicts with federalism, as it targets state-level disparities without infringing on state authority.
• Political: Addresses regional inequities in federal research funding, appealing to lawmakers from underrepresented states (e.g., sponsors from Mississippi, West Virginia, and New Hampshire). It promotes bipartisan support for science policy by emphasizing measurable outcomes, but could spark debates on funding formulas if they disadvantage high-research states.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Hyde-Smith, Cindy [R-MS]

Cosponsors (3)

Sen. Capito, Shelley Moore [R-WV], Sen. Hassan, Margaret Wood [D-NH], Sen. Coons, Christopher A. [D-DE]

Recent Actions

• 2025-06-10: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
• 2025-06-10: Introduced in Senate

Bill Versions

• IDeA Reauthorization Act of 2025 — issued 2025-06-10 — PDF (3 pages)